Shire Likely To Liquidate Jerini Holdings Except Firazyr
This article was originally published in The Pink Sheet Daily
Executive Summary
Outgoing Jerini execs could form new company to buy back two divisions and preclinical pipeline.
You may also be interested in...
Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders
The approval of ViroPharma/Lev's hereditary angioedema therapyCinryze on Oct. 10, with orphan status for prophylaxis only, leaves the window open for other C1 esterase inhibitors to claim the prize of orphan exclusivity for treatment of acute attacks. But ViroPharma thinks it can win that too
Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders
The approval of ViroPharma/Lev's hereditary angioedema therapyCinryze on Oct. 10, with orphan status for prophylaxis only, leaves the window open for other C1 esterase inhibitors to claim the prize of orphan exclusivity for treatment of acute attacks. But ViroPharma thinks it can win that too
Cinryze Approved To Prevent HAE Attacks
Other candidates lined up for acute indication